Iran starts mass-producing hemophilia drug

Business Materials 17 June 2015 18:05 (UTC +04:00)

Baku, Azerbaijan, June 17

By Umid Niayesh - Trend:

Iran started mass-production of the recombinant human factor VIII, Ebrahim Dinmohammadi, head of Samen Pharmaceutical Company said.

Factor VIII, an essential blood-clotting factor concentrated from donated blood plasma or alternatively recombinant factors, is used to restore hemostasis in individuals suffering from hemophilia.

The company achieved the technology to produce recombinant human factor VIII two years ago, however the mass-production delayed due to problems in importing needed equipment as a result of international sanctions against Iran, Dinmohammadi said, Iran's official IRNA news agency reported June 17.

He also said the company will produce some one million units of the medicine annually.

The production of recombinant human factor VIII in Iran will help hemophilia treatment be conducted in the country and save up to 60 million euro as the country cuts reliance on its imports, Dinmohammadi added.

Some 6,000 hemophiliacs live in Iran, 4,000 of which suffer from hemophilia A and need factor VIII regularly.

Edited by CN

Follow the author on Twitter: @UmidNiayesh